Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
This equation is commonly abbreviated as: C1V1 = C2V2
|Publication Number||Title||Priority Date|
|CN-114106788-A||Industrial circulating cooling liquid||2021-12-15|
|CN-114057804-A||Preparation method and application of polycarboxylic acid anti-wrinkle antibacterial finishing agent||2021-12-07|
|CN-114107270-A||L-aspartic acid beta-decarboxylase mutant||2021-12-07|
|CN-113974171-A||Slightly water-soluble composition, slightly water-soluble food or medicine and preparation method thereof||2021-11-08|
|CN-113908290-A||Multifunctional nano composite and preparation method and application thereof||2021-10-22|
|CN-113816876-A||Cardanol cyclic carbonate ether carboxylate anionic surfactant and preparation method thereof||2021-09-18|
|CN-113735724-A||Aspartic acid sodium diacetate and preparation method thereof||2021-09-08|
|CN-113604415-A||Application of recombinant bacillus subtilis and method for producing tetrahydropyrimidine by using wastewater generated in enzymatic synthesis of N-acetylneuraminic acid||2021-09-01|
|CN-113621549-A||Application of recombinant bacillus subtilis and method for producing tetrahydropyrimidine by using waste water generated in enzymatic synthesis of nicotinamide mononucleotide||2021-09-01|
|CN-113637624-A||Recombinant bacillus subtilis, application thereof and method for producing tetrahydropyrimidine by using waste water generated in glutathione synthesis by enzyme method||2021-09-01|
|36251573||2022-10-27||Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential Oral On-Demand Treatment for Hereditary Angioedema||Journal of medicinal chemistry|
|35483150||2022-06-01||Cineole alleviates the BPA-inhibited NETs formation by regulating the p38 pathway-mediated programmed cell death||Ecotoxicology and environmental safety|
|32363662||2020-08-01||Bisphenol A exposure disrupts aspartate transport in HepG2 cells||Journal of biochemical and molecular toxicology|
|30844808||2019-01-01||A Phase 2 Study of PCI-27483, a Factor VIIa Inhibitor in Combination with Gemcitabine for Advanced Pancreatic Cancer||Oncology|
|28470569||2018-01-01||Transport of BMAA into Neurons and Astrocytes by System xc||Neurotoxicity research|
|28548828||2017-09-15||Screening of Pro-Asp Sequences Exposed on Bacteriophage M13 as an Ideal Anchor for Gold Nanocubes||ACS synthetic biology|
|28682067||2017-07-27||Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs||Journal of medicinal chemistry|
|28257918||2017-05-01||Ceftriaxone-mediated upregulation of the glutamate transporter GLT-1 contrasts neurotoxicity evoked by kainate in rat organotypic spinal cord cultures||Neurotoxicology|
|26707656||2016-04-01||Persistent elevation of D-Aspartate enhances NMDA receptor-mediated responses in mouse substantia nigra pars compacta dopamine neurons||Neuropharmacology|
|25849139||2015-05-14||Aspartic acid based nucleoside phosphoramidate prodrugs as potent inhibitors of hepatitis C virus replication||Organic & biomolecular chemistry|
BOC Sciences can provide a wide variety of raw materials from upstream lines for automotive parts manufacturing, such as monomers, polymers and additives.
BOC Sciences supplies the necessary raw materials to help you manufacture ideal composites.
BOC Sciences can help our customers further understand the functionality and applicable requirements for raw materials in different healthcare segments.
BOC Sciences' seasoned experts can help you from upstream lines to arrive at the most appropriate solution to improve production and optimize your bottom line.